• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
              Advocacy & Research for Unlimited Lifespans

- - - - -

2 yr clinical trial, effects of micronized Resveratrol on hypertension

hypertension resveratrol in vivo

  • Please log in to reply
3 replies to this topic

#1 malbecman

  • Guest
  • 723 posts
  • 142
  • Location:Sunny CA

Posted 30 January 2017 - 04:50 PM



Exp Ther Med. 2017 Jan;13(1):295-301. doi: 10.3892/etm.2016.3958. Epub 2016 Dec 6.

The effect of resveratrol on hypertension: A clinical trial. Theodotou M1, Fokianos K2, Mouzouridou A3, Konstantinou C1, Aristotelous A1, Prodromou D3, Chrysikou A1.

The aim of this clinical trial was to investigate the effects of Evelor, a micronized formulation of resveratrol (RESV; 3,5,4'-trihydroxy-trans-stilbene), in patients with primary hypertension. RESV is a stilbenoid and phytoalexin produced by several plants in response to injury or attack by pathogens, such as bacteria and fungi. Patients included in the clinical trial were split into the following two groups, based on the severity of their disease: Group A (n=46), stage I hypertension [systolic blood pressure (SBP), 140-159 mmHg; diastolic blood pressure (DBP), 90-99 mmHg] and Group B (n=51), stage II hypertension (SBP, 160-179 mmHg; DBP, 100-109 mmHg). Each group was divided into two subgroups: A1 and B1, patients treated with standard antihypertensive therapy (A1, 10 mg Dapril; B1, 20 mg Dapril), and A2 and B2, patients treated with antihypertensive therapy (Dapril) plus Evelor. The present study aimed to determine the effects of Evelor, in addition to the standard hypertension treatment, and its effect on the hepatic enzymes serum glutamate-pyruvate transaminase (SGPT) and gamma-glutamyl transferase (gamma-GT). Following the trial, which lasted two years (October 2010 to October 2012), the mean blood pressure of both groups lay within the normal range, indicating that blood pressure was efficiently controlled. The results of the present study demonstrate that the addition of RESV to standard antihypertensive therapy is sufficient to reduce blood pressure to normal levels, without the need for additional antihypertensive drugs. In addition, statistical analysis of the results identified a significant reduction in plasma concentration levels of SGPT (P<0.001) and gamma-GT (P<0.001) with the addition of RESV, indicating that RESV prevents liver damage.


hypertension; nitric oxide; resveratrol; vascular dysfunction

PMID: 28123505

  • Informative x 2
  • unsure x 1

#2 Anthony_Loera

  • Life Member
  • 3,128 posts
  • 713
  • Location:Miami Florida

Posted 31 January 2017 - 07:52 PM

Micronized Resveratrol = The bomb!


Sorry, I but like good news..



  • Agree x 1

sponsored ad

  • Advert
Click HERE to rent this advertising spot to support LongeCity (this will replace the google ad above).

#3 bixbyte

  • Guest
  • 552 posts
  • 45
  • Location:End of the Galaxy
  • NO

Posted 03 March 2017 - 03:03 AM

The Sprint Study will teach you a better perspective on how to lower your BP and extend longevity with a combo of Heart Meds.  :)





sponsored ad

  • Advert
Click HERE to rent this advertising spot to support LongeCity (this will replace the google ad above).

#4 Captain Obvious

  • Guest
  • 77 posts
  • 25
  • Location:Finland
  • NO

Posted 13 March 2017 - 07:17 AM

The dosage was only 50 mg Evelor (micronized resveratrol)? That's seems like an incredibly low dose compared to what people are normally supplementing (200-1000 mg) daily.

I hope this study will be repeated so we can see if this was just a marketing effort. Suspiciously the company producing Evelor is located in Cyprus and the study was done by researchers from Cyprus...

Edited by Captain Obvious, 13 March 2017 - 07:22 AM.

  • Agree x 1

Also tagged with one or more of these keywords: hypertension, resveratrol, in vivo

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users